Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy
Background: Current treatment guidelines for arrhythmogenic right ventricular cardiomyopathy (ARVC) mainly emphasize on prevention of ventricular arrhythmic events. Despite the progressive nature of ARVC, therapeutic options focusing on decelerating disease progression are scarce.Methods and Results...
Guardado en:
Autores principales: | Bin Tu, Lingmin Wu, Lihui Zheng, Shangyu Liu, Lishui Sheng, Limin Liu, Zhenghui Zhu, Yan Yao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/83e4375c2c1444a3a25151da276ac3f6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity
por: Anneline S. J. M. te Riele, et al.
Publicado: (2021) -
Layer-Specific Global Longitudinal Strain Predicts Arrhythmic Risk in Arrhythmogenic Cardiomyopathy
por: Diego Segura-Rodríguez, et al.
Publicado: (2021) -
Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy—A Multicenter Study
por: Alessio Gasperetti, et al.
Publicado: (2021) -
Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy
por: Domenico Corrado, et al.
Publicado: (2021) -
Autoimmune Myocarditis and Arrhythmogenic Mitral Valve Prolapse: An Unexpected Overlap Syndrome
por: Andrea Villatore, et al.
Publicado: (2021)